Want to join the conversation?
$MYL said it is taking immediate action to enhance access to EpiPen Auto-Injector by expanding its existing programs to help patients who are facing the burden of higher out-of-pocket costs. Company is reducing patient cost of EpiPen through a savings card which covers up to $300 for their EpiPen 2-Pak, thereby reducing out-of-pocket cost by 50%.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!